Search

Your search keyword '"Saleh Y."' showing total 732 results
Start Over Author "Saleh Y."
732 results on '"Saleh Y."'

252. Temporallappenepilepsien

Author

Saleh, Y., primary, Kirchner, A., additional, Pauli, E., additional, Hilz, M.J., additional, Neundörfer, B., additional, and Stefan, H., additional

Published
2000
Full Text
View/download PDF

255. Normal Circulating PTH in Saudi Healthy Individuals with Hypovitaminosis D.

Author

Al-Saleh, Y., Al-Daghri, N. M., Alkharfy, K. M., Al-Attas, O. S., Alokail, M. S., Al-Othman, A., Sabico, S., and Chrousos, G. P.

Subjects
*BLOOD plasma, *STEROID hormones, *VITAMIN D, *VITAMIN deficiency, *BLOOD pressure
Abstract

Recent studies in the Middle East have shown an increased incidence of vitamin D defi ciency across this region of year-round sunlight. There is scarcity of information, however, as to the levels of 1,25-dihydroxyvitamin D [1,25(OH) 2 D], the active form of vitamin D, and its associations with cardiometabolic parameters in an Arab cohort and this study aims to fi ll this gap. In a cross-sectional study, 33 male and 43 female (22 children and 54 adults, total 76) Saudis with previously established low levels of serum 25-hydroxyvitamin D [25(OH)D] ( < 50 ng/ml or 20 nmol/l) were recruited. Anthropometrics were obtained and fasting blood samples were taken for a routine measurement of glucose, lipid profi le, calcium, and albumin, while serum 25(OH)D, 1,25-(OH) 2 D, and intact PTH were quantifi ed using specifi c ELISAs. Serum calcium, intact PTH, and 1,25(OH) 2 D were all within the normal range in both children and adults in both genders. In all subjects, serum 1,25(OH) 2 D was not associated with intact PTH, while circulating 1,25(OH)D inversely correlated with systolic blood pressure (p = 0.01) and waist circumference (p = 0.04). Thus, vitamin D defi cient Saudi children and adults with normal levels of 1,25- (OH) 2 D also had normal circulating calcium and PTH. This study suggests that local cutoff s should be set that will be of clinical signifi cance in the identifi cation of those at true risk for harder endpoints, such as secondary hyperparathyroidism and bone-related diseases. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

256. Heat and Mass Transfer in Moist Soil, Part I. Formulation and Testing.

Author

Moukalled, F. and Saleh, Y.

Subjects
*MASS transfer, *NUMERICAL analysis, *SOIL moisture, *FINITE volume method, *TESTING
Abstract

An unsteady two-dimensional model of heat and mass transfer through soil is implemented within a finite-volume-based numerical method. The model follows a phenomenological formulation for the transfer processes with temperature and matric potential (?) as the dependent variables. The finite-volume method being inherently conservative, the mass imbalance problem reported in the literature when employing the ?-based formulation with other numerical methods is prevented. A partial elimination algorithm is applied within the iterative solution procedure to increase its implicitness and improve its robustness. The accuracy of the model is established by solving the following three test problems: temperature distribution in dry soil; moisture distribution in isothermal soil; and coupled heat and water vapor diffusion in soil. Results are presented in the form of temporal profiles of temperature and moisture content and compared against analytical values. Excellent agreement is obtained, with numerical profiles falling on top of theoretical values. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

266. Late presentation of cancers in Zaria: An intractable problem

Author

Saleh Y Sabo, Emmanuel A. Ameh, and Ilyasu Muhammad

Subjects
Oncology, Male, medicine.medical_specialty, Health Services Needs and Demand, Time Factors, business.industry, Culture, Public Health, Environmental and Occupational Health, Nigeria, Surgery, Late presentation, Infectious Diseases, Text mining, Internal medicine, Neoplasms, medicine, Humans, Female, Risk factor, business, Child, Poverty, Referral and Consultation

272. Design of Supply Chain Network to Reduce Impacts of Damages during Shipping.

Author

Abushaega, Mastoor M., Daehy, Yahya H., Alghamdi, Saleh Y., Krishnan, Krishna K., and Khamaj, Abdulrahman

Subjects
*SUPPLY chains, *FALSE positive error, *LOADING & unloading
Abstract

Recently, the expand of industrial market has led to have long supply chain network. During the long shipment, the probability of having damaged products is likely to occur. The probability of having damaged products is different between stages and that could lead to higher percentage of damaged products when arrived at retailers. Many companies have rejected the entire shipment because the damaged product percentage was higher than that agreed on. Decision-makers have tried to reduce the percentage of damaged products that happened because the transit, loading unloading the shipment, and natural disasters. Companies started to implement recovery centers in the supply chain network in order to return their system steady statues. Recovery models have been developed in this paper to reduce the damaged percentage at minimum costs to do so. Results show that the possibility of implementing an inspection unit and a recovery centers in the system before sending the entire shipment to the retailer based on examining a sample size that has been selected randomly from the shipment and the minimum cost of committing type I and type II errors. Designing a methodology to minimize the total cost associated with the supply chain system when there is a possibility of damage occurring during shipping is the objective of this research. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

278. Harnessing flexibility potential of flexible carbon capture power plants for future low carbon power systems: Review.

Author

Abdilahi, Abdirahman M., Mustafa, Mohd Wazir, Abujarad, Saleh Y., and Mustapha, Mamunu

Subjects
*CARBON sequestration, *FLEXIBILITY testing (Physiology), *ELECTRIC power systems, *ELECTRICITY, *POWER plants
Abstract

Fossil-fired power plants retrofitted with Carbon Capture and Storage (CCS) may have operational benefits for future low carbon power systems. This paper aims to review state of the art literature with the objective to identify whether carbon capture power plants would bring flexibility within future lower carbon power systems. To achieve this objective, at first, the work investigates flexible operation of CCS technology. In particular, flexibility enabling mechanisms and factors that affect the flexible operation of CCS are reviewed. Flexibility requirements and provision assessment tools/metrics for future low carbon power systems are reviewed with the aim to identify the favourite properties required for future low carbon technologies. The work then presents how flexible CCS might improve the conventional power plant flexibility properties. Moreover, the paper presents the value of flexible operation of CCS for different stakeholders while it also identifies different influencing factors of optimal plant operation and profitability. The different power system services that the CCS-equipped plants might serve are also presented. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

280. Effects of substrate material on the electrical properties of self-assembled InAs quantum dots-based laser structures.

Author

Al Huwayz, M., Jameel, D. A., Alotaibi, S., Alhassan, S., Almalki, A., Al Saqri, N., Al Saleh, Y., Alhassni, A., Almunyif, A., Lemine, O. M., Salhi, A., and Henini, M.

Subjects
*QUANTUM dots, *INDIUM gallium arsenide, *LASERS, *AUDITING standards, *GALLIUM arsenide, *ELECTRON traps
Abstract

In this work, the effects of the substrate material on the electrical properties of self-assembled InAs quantum dots (QDs)-based laser structures have been reported. Two InAs QD laser structures with the same active regions deposited on GaAs and Si substrates utilizing strain reducing layer (SRL) containing GaAs/InGaAs have been investigated using current–voltage (I–V), capacitance–voltage, and Deep-Level Transient Spectroscopy (DLTS) techniques. The I–V measurements illustrated that the rectification ratio (IF/IR) and built-in potential (ϕB) for the sample deposited on Si substrate are higher than that of sample deposited on GaAs substrate. However, the series resistance (Rs) of the InAs QDs deposited on Si substrate is lower than that of the InAs QDs deposited on GaAs substrate. The DLTS and Laplace-DLTS measurements showed that the number of traps in InAs QDs/GaAs devices is lower than that in InAs QDs/Si devices, corroborating with I–V results. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

282. Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma.

Author

Zsebik, B., Symonowicz, K., Saleh, Y., Ziolkowski, P., Bronowicz, A., and Vereb, G.

Subjects
*PHOTOCHEMOTHERAPY, *CYSTEINE proteinases, *PHOTOSENSITIZERS, *EOSIN, *VASCULAR endothelial growth factors, *TUMOR necrosis factors, *LABORATORY rats
Abstract

Objectives: Photodynamic therapy (PDT) and inhibition of cathepsin B proteases by cystatin (cysteine proteinase inhibitor, CPI) are potential new tumour treatment modalities. We have investigated the efficacy of PDT and CPI alone and in combination on a solid mammary carcinoma transplanted into Wistar rats. Materials and Methods: Intraperitoneally injected single doses of chlorine e6 or HpD as photosensitizers were excited at 630 nm (90 J/cm2). CPI (500 µg per animal) was injected around the tumour daily during the 8-day treatment. Inoculation of tumour was either on day 1 of the protocol, or 8 days before. On day 8, tumour size was measured, tumour necrosis and vascularization were determined based on haematoxylin and eosin (H&E)-stained sections and serum vascular endothelial growth factor (VEGF) levels measured using an enzyme-linked immunosorbent assay kit. Results: No differences (two-wayanova) were found for treatments started with various time lags. At doses where CPI or PDT alone had no or negligible effect, their combination caused a marked ( P < 0.001) decrease in serum VEGF, paralleled by a significant decrease in tumour size and number of capillary vessels, and a significant increase in necrosis (up to 80% of the tumour tissue). Conclusions: The combination of PDT and CPI could be a useful approach in tumour therapy as the two agents appear to be synergistic and probably decrease VEGF production by the tumour tissue. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

283. Overcharge studies of carbon fiber composite-based lithium-ion cells

Author

Hossain, S., Kim, Y.-K., Saleh, Y., and Loutfy, R.

Subjects
*LITHIUM cells, *CARBON fibers, *ELECTRON microscopy, *SCANNING electron microscopy
Abstract

Abstract: Prototype lithium-ion pouch cells of 5.5Ah have been fabricated with carbon fiber composite anodes, LiCoO2 cathodes, and LiPF6 electrolyte to investigate the overcharge characteristics of these cells at the 1C rate. The cells were made with anode to cathode capacity (A/C) ratios of 1.0 and 1.1. The cells were first examined for charge–discharge characteristics at different rates in order to determine the delivered capacity, specific energy and energy density and rate capability, and to ensure that the cells are suitable for overcharge studies. The current, voltage, and temperature responses during overcharge to 12V were recorded. Maximum temperatures of 65 and 85°C were observed with the cells with A/C equal to 1.1 and 1.0, respectively. The overcharged cells were dissected in an inert atmosphere and their components were analyzed using scanning electron microscopy and x-ray fluorescence spectroscopy. It is believed that a relatively low amount of heat is generated with carbon fiber composite-based lithium-ion cells and a separator shutdown mechanism is operative in the cell system which prevents fire or explosion during overcharge. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

285. The groundwater quality assessment for domestic use in Malaysia: A case study of Sabah rural area.

Author

Hashim, M., Japiring, H. M., Setyowati, D. L., Mahat, H., Nayan, N., Saleh, Y., Norkhaidi, S. B., Zahid, M. S., Razak, Rafiza Abd, Abdullah, Mohd Mustafa Al Bakri, Rahim, Shayfull Zamree Abd, Tahir, Muhammad Faheem Mohd, Mortar, Nurul Aida Mohd, and Jamaludin, Liyana

Subjects
*GROUNDWATER quality, *TOTAL suspended solids, *RESIDENTIAL water consumption, *RURAL geography, *GROUNDWATER monitoring, *WATER quality
Abstract

In rural areas of Sabah, Malaysia, the groundwater source is the only water supply for domestic consumption. Therefore, the monitoring of groundwater quality is essential to adhere to the standards by Malaysia's Department of Environment. This article seeks to evaluate the groundwater quality through the quantitative analysis, and the sampling carried out between January and March 2019. Among national water quality standards sampled including dissolved oxygen, pH, ammonia nitrogen, and total suspended solids. The result showed that the chemical oxygen demand was above the standards, >197mg/l (Station 5) and fall into Class V. However, the index of water quality for all stations indicate Class II with the lowest in Station 5 (80 per cent) and the highest in Station 6 (90 per cent). All stations showed clean category except for Station 5 (moderately polluted). This study also implicates that the water quality assessment could act as a tool in monitoring the groundwater. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

286. Effectiveness of the implementation of geography field study among form six students.

Author

Mahat, H., Pauzan, N. A. A. Wan, Hashim, M., Saleh, Y., Nayan, N., Norkhaidi, S. B., Suhendro, Razak, Rafiza Abd, Abdullah, Mohd Mustafa Al Bakri, Rahim, Shayfull Zamree Abd, Tahir, Muhammad Faheem Mohd, Mortar, Nurul Aida Mohd, and Jamaludin, Liyana

Subjects
*GEOGRAPHY, *FIELD research, *STUDENT interests, *STATISTICAL sampling, *SOFT skills, *PEARSON correlation (Statistics), *REGRESSION analysis
Abstract

This study aims to look at the effectiveness of Geography fieldwork study among form six students in Machang, Kelantan. A quantitative approach was applied in this study by using a questionnaire as an instrument. A simple random sampling method was used for the selection of respondents and the total number of respondents was 80 form six students who were taking Geography in some selected schools in the Machang district in Kelantan. Four study variables were used, namely interest, understanding, skills and effectiveness, in the implementation of the Geography fieldwork study. Descriptive analysis was used to examine the level of each variable I, II, III and IV, and inferential analysis (Pearson's correlation and regression) was used to examine the relationships and influential contributions of each study variable. The findings showed that all of the variables, namely interest (M = 2.89, SP = 0.32), understanding (M = 2.87, SP = 0.32), manipulative skills (M = 2.33, SP = 0.50), soft skills (M = 2.75, SP = 0.44) and the effectiveness of the implementation (M = 2.90, SP = 0.30) were at a moderate level. The results of the Pearson's correlation analysis also found that there was a significant positive relationship between the interest and understanding variables (r = 0.538, p <0.005), understanding and manipulative skills (r = 0.556, p <0.005), manipulative skills and soft skills (r = 0.595, p <0.005) and soft skills with effectiveness (r = 0.677, p <0.005). In addition, regression analysis showed that soft skills had the highest impact on the effectiveness of the Geography field study by 45.8% with R2 = 0.581, F (26.030) = 0.324, P<0.05. In conclusion, this study finds that students show an interest, understanding, and skills in the effectiveness of the Geography field study. This shows that the implementation of Geography field study in schools can bring about change among students, and indicates that an effective Geography field study can enhance students' interest, understanding and skills in the subject of Geography and is able to give students the opportunity to be more innovative and to think creatively. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

287. Organic optoelectronic copolymer involving PVK and F8T2: Synthesis and characterization.

Author

Mbarek, M., Almoneef, M.M., ben Saleh, Y., and Alimi, K.

Subjects
*FLUORESCENT polymers, *LIGHT absorption, *OPTICAL properties, *ENERGY transfer, *INFRARED absorption
Abstract

[Display omitted] • A new PVK-F8T2 dye was synthesized via oxidative pathway. • Structural, optical and electronic properties were investigated. • Establishment of a great structure-properties relationship. • This new copolymer seems to be a good candidature for optoelectronic devices. • Use of time-resolved to predict the energy transfer from PVK to F8T2. The synthesis of new fluorescent polymers based on π-conjugated chains is a major challenge for organic electronic. The materials must be soluble, stable over long periods and able to be produced with a high yield. In particular, poly (vinylcarbazole), poly (fluorenes), and poly (thiophene) partially meet these criteria. In this study, new soluble copolymers PVK-F8T2 was synthesized from poly(9-vinylcarbazole) (PVK) and poly[(9,9-dioctylfluorenyl-2,7-diyl)-co-(bithiophène)] (F8T2). As these materials are highly luminescent and green-emitting, they have good chemical and thermal stability and can be easily functionalized. Here, the vibrational and optical properties of PVK-F8T2 was studied using several different techniques, including Infrared absorption, Raman scattering, thermogravimetric analysis (TGA), UV–visible optical absorption, and both stationary and transient photoluminescence. The novel copolymer shows an increase of thermal stability compared to the two original polymers (PVK and F8T2). The stationary and transient photoluminescence reveal an energy transfer from PVK to F8T2. This study indicates that these copolymers are good candidates for photophysical applications. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

288. Follow up the antibodies titer against Newcastle disease virus in broiler breeders using ELISA test.

Author

Isihak, F. A., Hassan, S. M., Shaker, B. Z., and Saleh, Y. A.

Subjects
*IMMUNOGLOBULINS, *NEWCASTLE disease virus, *TITERS, *BROILER chickens, *BROILER chicken diseases, *ANIMAL vaccination, *ENZYME-linked immunosorbent assay
Abstract

The study period carried out from 25 April 2018 till 21 May 2019 through the rearing and production period including totally of 24000 birds (20800 females, 3200 males). The number of tested blood samples was 452 divided to 255 samples at the rearing period, 143 samples at the production period and 54 samples of offspring. The results of antibodies titer in the sera of non-vaccinated broiler breeders obtained by ELISA showed the maternal derived antibodies titer for 28 samples at 0-5 week/day of age was 5716±612.7, this titer decreased gradually at 3-1 week/day age till to 1075±234) Then the titer was elevated increasingly after vaccination with both live attenuated and inactivated vaccines and reach to peak 37512±2049.4 at 20-1 week/day age. Whereas the bimodal graduation of antibodies titer showed at production period till to end of study. The mean of maternally antibodies titer in the tested sera of the offspring chicks 0-1 week/day that hatched from parent flocks at 32, 39 and 48 weeks of age was 9012±872.4, 6591±368.1 and 4831±982.7 respectively. Thus, we concluded the repetitive vaccination of broiler breeders flock with live vaccine as well as inactivated vaccine is very necessary in endemic areas and ELISA is a good serological test for following, checking and monitoring of immune status of poultry flocks periodically. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

289. Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit

Author

Yousef Al Saleh, Noor Al Busaidi, Waleed Al Dahi, Munawar Almajnoni, Al Saeed Mohammed, Khalid Alshali, Mostafa Al-Shamiri, Saud Al Sifri, Mohammed Arafah, Siew Pheng Chan, Hassan El-Tamimi, Khadija Hafidh, Mohamed Hassanein, Ashraf Shaaban, Ali Sultan, Guido Grassi, Al Saleh, Y, Al Busaidi, N, Al Dahi, W, Almajnoni, M, Mohammed, A, Alshali, K, Al-Shamiri, M, Al Sifri, S, Arafah, M, Chan, S, El-Tamimi, H, Hafidh, K, Hassanein, M, Shaaban, A, Sultan, A, and Grassi, G

Subjects
Type 2 diabetes mellitu, Clinical inertia, Middle East, Adherence, Gliclazide, Hypertension, Single-pill combination, Pharmacology (medical), General Medicine, Individualised therapy
Abstract

Type 2 diabetes mellitus (T2DM) and hypertension are leading risk factors for death and disability in the Middle East. Both conditions are highly prevalent, underdiagnosed and poorly controlled, highlighting an urgent need for a roadmap to overcome the barriers to optimal glycaemic and blood pressure management in this region. This review provides a summary of the Evidence in Diabetes and Hypertension Summit (EVIDENT) held in September 2022, which discussed current treatment guidelines, unmet clinical needs and strategies to improve treatment outcomes for patients with T2DM and hypertension in the Middle East. Current clinical guidelines recommend strict glycaemic and blood pressure targets, presenting several treatment options to achieve and maintain these targets and prevent complications. However, treatment targets are infrequently met in the Middle East, largely due to high clinical inertia among physicians and low medication adherence among patients. To address these challenges, clinical guidelines now provide individualised therapy recommendations based on drug profiles, patient preferences and management priorities. Efforts to improve the early detection of prediabetes, T2DM screening and intensive, early glucose control will minimise long-term complications. Physicians can use the T2DM Oral Agents Fact Checking programme to help navigate the wide range of treatment options and guide clinical decision-making. Sulfonylurea agents have been used successfully to manage T2DM; a newer agent, gliclazide MR (modified release formulation), has the advantages of a lower incidence of hypoglycaemia with no risk of cardiovascular events, weight neutrality and proven renal benefits. For patients with hypertension, single-pill combinations have been developed to improve efficacy and reduce treatment burden. In conjunction with pragmatic treatment algorithms and personalised therapies, greater investments in disease prevention, public awareness, training of healthcare providers, patient education, government policies and research are needed to improve the quality of care of patients with T2DM and/or hypertension in the Middle East.

Published
2023

291. Is It Justified to Use Liver Grafts From Living Donors for Retransplant? A Single-Center Experience

Author

Hazem M Zakaria, Ahmed S. Zidan, Mark Sturdevant, Waleed Al-Hamoudi, Roberto Troisi, Dieter C. Broering, Ali Albenmousa, Yahia Saleh, Yasser Elsheikh, Saleh Alabbad, Zakaria, H., Saleh, Y., Zidan, A., Sturdevant, M., Alabbad, S., Elsheikh, Y., Al-Hamoudi, W., Albenmousa, A., Troisi, R., and Broering, D.

Subjects
Adult, Male, Reoperation, medicine.medical_specialty, Graft failure, Time Factors, Adolescent, medicine.medical_treatment, Single Center, Primary disease, Cold Ischemia Time, Risk Assessment, Liver disease, Young Adult, Postoperative Complications, Risk Factors, medicine, Living Donors, Humans, Child, Aged, Retrospective Studies, Transplantation, business.industry, Infant, Patient survival, Living-donor liver retransplant, Middle Aged, medicine.disease, Surgery, Liver Transplantation, Hepatic artery thrombosis, Treatment Outcome, Hepatic artery thrombosi, Deceased-donor liver retransplant, Child, Preschool, Female, Hepatectomy, business, Graft dysfunction
Abstract

Objectives Liver retransplant is considered the only hope for patients with irreversible graft failure after primary transplant. In most Western centers, retransplantis done mainly from deceased donors; so far, only few published studies have reported on outcomes of liver retransplant with living donors. In this study, our aim was to analyze the outcomes of living-donor liver retransplant. Materials and methods Patients who underwent liver retransplant between February 2011 and February 2019 were included in the study. Preoperative, operative, and postoperative data were analyzed. Results from 2 patient groups were compared: liver retransplant with living donors and liver retransplant with deceased donors. Results Thirty-two patients underwent liver retransplant (21 adult and 11 pediatric patients). The most common indications for liver retransplant were hepatic artery thrombosis (28.5%) and primary graft nonfunction (23.8%) in adults and hepatic artery thrombosis (45.5%) and chronic rejection (36.4%) in pediatric patients. Seventeen retransplant patients (53.1%) required early retransplant (within 1 mo), mainly due to hepatic artery thrombosis (52.9%) and primary graft nonfunction (35.3%). Late retransplant was mainly due to chronic rejection (40%) and recurrence of primary disease (26.7%). Seventeen patients (53.1%) underwent living-donor retransplant, and 5 donors underwent robotic right hepatectomy. Graft and patient survival rates at 1, 3, and 5 years were 81.3% for living-donor and 51.4% for deceased-donor liver retransplant recipients (P = .08). On multivariate analyses, we observed significant differences between both groups in pretransplant Model for End-Stage Liver Disease and Pediatric End-Stage Liver Disease scores (P = .05), preoperative international normalized ratio (P = .012), and cold ischemia time (P = .046). Conclusions The use of living donors for liver retransplant, despite its technical demand, was shown to be a safe and feasible option, especially when there is scarcity of deceased donors.

Published
2019

292. Clinical presentation, aetiology and outcomes of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study

Author

Habib G., Erba P. A., Iung B., Donal E., Cosyns B., Laroche C., Popescu B. A., Prendergast B., Tornos P., Sadeghpour A., Oliver L., Vaskelyte J. -J., Sow R., Axler O., Maggioni A. P., Lancellotti P, C P Gale, B Beleslin, A Budaj, O Chioncel, N Dagres, N Danchin, J Emberson, D Erlinge, M Glikson, A Gray, M Kayikcioglu, A P Maggioni, V K Nagy, A Nedoshivin, A-S Petronio, J Roos-Hesselink, L Wallentin, U Zeymer, G Habib, P Lancellotti, B Cosyns, E Donal, P Erba, B Iung, B A Popescu, B Prendergast, P Tornos, M Andarala, C Berle, A Brunel-Lebecq, E Fiorucci, C Laroche, V Missiamenou, C Taylor, N N Ali Tatar-Chentir, M Al-Mallah, M Astrom Aneq, G Athanassopoulos, L P Badano, S Benyoussef, E Calderon Aranda, N M Cardim, K-L Chan, I Cruz, T Edvardsen, G Goliasch, A Hagendorff, K Hristova, O Kamp, D-H Kang, W Kong, S Matskeplishvili, M Meshaal, M Mirocevic, A N Neskovic, M Pazdernik, E Plonska-Gosciniak, M Raissouni, R Ronderos, L E Sade, A Sadeghpour, A Sambola, S Sengupta, J Separovic-Hanzevacki, M Takeuchi, E Tucay, A C Tude Rodrigues, A Varga, J Vaskelyte, K Yamagata, K Yiangou, H Zaky, I Granada, M Mahia, S Ressi, F Nacinovich, A Iribarren, P Fernandez Oses, G Avegliano, E Filipini, R Obregon, M Bangher, J Dho, L Cartasegna, M L Plastino, V Novas, C Shigel, G Reyes, M De Santos, N Gastaldello, M Granillo Fernandez, M Potito, G Streitenberger, P Velazco, J H Casabé, C Cortes, E Guevara, F Salmo, M Seijo, F Weidinger, M Heger, R Brooks, C Stöllberger, C-Y Ho, L Perschy, L Puskas, C Binder, R Rosenhek, M Schneider, M-P Winter, E Hoffer, M Melissopoulou, E Lecoq, D Legrand, S Jacquet, M Massoz, L Pierard, S Marchetta, R Dulgheru, C D Emal, C Oury, S Droogmans, D Kerkhove, D Plein, L Soens, C Weytjens, A Motoc, B Roosens, I Lemoine, I Rodrigus, B Paelinck, B Amsel, P Unger, D Konopnicki, C Beauloye, A Pasquet, J L Vanoverschelde, S Pierard, D Vancraeynest, F Sinnaeve, J L Andrade, K Staszko, R Dos Santos Monteiro, M H Miglioranza, D L Shuha, M Alcantara, V Cravo, L Fazzio, A Felix, M Iso, C Musa, A P Siciliano, F Villaca Filho, A Rodrigues, F Vilela, J Braga, R Silva, D Rodrigues, L Silva, S Morhy, C Fischer, M Vieira, T Afonso, J Abreu, S N Falcao, V A Moises, A Gouvea, F J Mancuso, A C Souza, C Y Silva, G João, C S Abboud, R Bellio de Mattos Barretto, A Ramos, R Arnoni, J E Assef, D J Della Togna, D Le Bihan, L Miglioli, A P Romero Oliveira, R Tadeu Magro Kroll, D Cortez, C L Gelape, M D C Peirira Nunes, T C De Abreu Ferrari, K Hay, V Le, M Page, F Poulin, C Sauve, K Serri, C Mercure, J Beaudoin, P Pibarot, I A Sebag, L G Rudski, G Ricafort, B Barsic, V Krajinovic, M Vargovic, D Lovric, V Reskovic-Luksic, J Vincelj, S Jaksic Jurinjak, V Yiannikourides, M Ioannides, C Pofaides, V Masoura, J Pudich, A Linhart, M Siranec, J Marek, K Blechova, M Kamenik, R Pelouch, Z Coufal, M Mikulica, M Griva, E Jancova, M Mikulcova, M Taborsky, J Precek, M Jecmenova, J Latal, J Widimsky, T Butta, S Machacek, R Vancata, J Spinar, M Holicka, F Pow Chon Long, N Anzules, A Bajana Carpio, G Largacha, E Penaherrera, D Moreira, E Mahfouz, E Elsafty, A Soliman, Y Zayed, J Aboulenein, M Abdel-Hay, A Almaghraby, M Abdelnaby, M Ahmed, B Hammad, Y Saleh, H Zahran, O Elgebaly, A Saad, M Ali, A Zeid, R El Sharkawy, A Al Kholy, R Doss, D Osama, H Rizk, A Elmogy, M Mishriky, P Assayag, S El Hatimi, S Hubert, J-P Casalta, F Gouriet, F Arregle, S Cammilleri, L Tessonnier, A Riberi, E Botelho-Nevers, A Gagneux-Brunon, R Pierrard, C Tulane, S Campisi, J-F Fuzellier, M Detoc, T Mehalla, D Boutoille, A S Lecompte, M Lefebvre, S Pattier, O Al Habash, N Asseray-Madani, C Biron, J Brochard, J Caillon, C Cueff, T Le Tourneau, R Lecomte, M M Magali Michel, J Orain, S Delarue, M Le Bras, J-F Faucher, V Aboyans, A Beeharry, H Durox, M Lacoste, J Magne, D Mohty, A David, V Pradel, V Sierra, A Neykova, B Bettayeb, S Elkentaoui, B Tzvetkov, G Landry, C Strady, K Ainine, S Baumard, C Brasselet, C Tassigny, V Valente-Pires, M Lefranc, B Hoen, B Lefevre, E Curlier, C Callier, N Fourcade, Y Jobic, S Ansard, R Le Berre, F Le Ven, M-C Pouliquen, G Prat, P Le Roux, F Bouchart, A Savoure, C Alarcon, C Chapuzet, I Gueit, C Tribouilloy, Y Bohbot, F Peugnet, M Gun, X Duval, X Lescure, E Ilic-Habensus, N Sadoul, C Selton-Suty, F Alla, F Goehringer, O Huttin, E Chevalier, R Garcia, V Le Marcis, P Tattevin, E Flecher, M Revest, C Chirouze, K Bouiller, L Hustache-Mathieu, T Klopfenstein, J Moreau, D Fournier, A-S Brunel, P Lim, L Oliver, J Ternacle, A Moussafeur, P Chavanet, L Piroth, A Salmon-Rousseau, M Buisson, S Mahy, C Martins, S Gohier, O Axler, F Baumann, S Lebras, C Piper, D Guckel, J Börgermann, D Horstkotte, E Winkelmann, B Brockmeier, D Grey, G Nickenig, R Schueler, C Öztürk, E Stöhr, C Hamm, T Walther, R Brandt, A-C Frühauf, C T Hartung, C Hellner, C Wild, M Becker, S Hamada, W Kaestner, K Stangl, F Knebel, G Baldenhofer, A Brecht, H Dreger, C Isner, F Pfafflin, M Stegemann, R Zahn, B Fraiture, C Kilkowski, A-K Karcher, S Klinger, H Tolksdorf, D Tousoulis, C Aggeli, S Sideris, E Venieri, G Sarri, D Tsiapras, I Armenis, A Koutsiari, G Floros, C Grassos, S Dragasis, L Rallidis, C Varlamos, L Michalis, K Naka, A Bechlioulis, A Kotsia, L Lakkas, K Pappas, C Papadopoulos, S Kiokas, A Lioni, S Misailidou, J Barbetseas, M Bonou, C Kapelios, I Tomprou, K Zerva, A Manolis, E Hamodraka, D Athanasiou, G Haralambidis, H Samaras, L Poulimenos, A Nagy, A Bartykowszki, E Gara, K Mungulmare, R Kasliwal, M Bansal, S Ranjan, A Bhan, M Kyavar, M Maleki, F Noohi Bezanjani, A Alizadehasl, S Boudagh, A Ghavidel, P Moradnejad, H R Pasha, B Ghadrdoost, D Gilon, J Strahilevitz, M Wanounou, S Israel, C d'Agostino, P Colonna, L De Michele, F Fumarola, M Stante, N Marchionni, V Scheggi, B Alterini, S Del Pace, P Stefano, C Sparano, N Ruozi, R Tenaglia, D Muraru, U Limbruno, A Cresti, P Baratta, M Solari, C Giannattasio, A Moreo, B De Chiara, B Lopez Montero, F Musca, C A Orcese, F Panzeri, F Spano, C F Russo, O Alfieri, M De Bonis, S Chiappetta, B Del Forno, M Ripa, P Scarpellini, C Tassan Din, B Castiglioni, R Pasciuta, S Carletti, D Ferrara, M Guffanti, G Iaci, E Lapenna, T Nisi, C Oltolini, E Busnardo, U Pajoro, E Agricola, R Meneghin, D Schiavi, F Piscione, R Citro, R M Benvenga, L Greco, L Soriente, I Radano, C Prota, M Bellino, D Di Vece, F Santini, A Salsano, G M Olivieri, F Turrini, R Messora, S Tondi, A Olaru, V Agnoletto, L Grassi, C Leonardi, S Sansoni, S Del Ponte, G M Actis Dato, A De Martino, N Ohte, S Kikuchi, K Wakami, K Aonuma, Y Seo, T Ishizu, T Machino-Ohtsuka, M Yamamoto, N Iida, H Nakajima, Y Nakagawa, C Izumi, M Amano, M Miyake, K Takahashi, I Shiojima, Y Miyasaka, H Maeba, Y Suwa, N Taniguchi, S Tsujimoto, T Kitai, M Ota, S Yuda, S Sasaki, N Hagiwara, K Yamazaki, K Ashihara, K Arai, C Saitou, S Saitou, G Suzuki, Y Shibata, N Watanabe, S Nishino, K Ashikaga, N Kuriyama, K Mahara, T Okubo, H Fujimaki, H Shitan, H Yamamoto, K Abe, M Terada, S Takanashi, M Sata, H Yamada, K Kusunose, Y Saijo, H Seno, O Yuichiro, T Onishi, F Sera, S Nakatani, H Mizuno, K Sengoku, S W Park, K Eun Kyoung, L Ga Yeon, J-W Hwang, C Jin-Oh, S-J Park, L Sang-Chol, C Sung-A, S Y Jang, R Heo, S Lee, J-M Song, E Jung, J Plisiene, A Dambrauskaite, G Gruodyte, R Jonkaitiene, V Mizariene, J Atkocaityte, R Zvirblyte, R Sow, A Codreanu, T Staub, C Michaux, E C L De la Vega, L Jacobs-Orazi, C Mallia Azzopardi, R G Xuereb, T Piscopo, J Farrugia, M Fenech, E Pllaha, C Vella, D Borg, R Casha, L Grib, E Raevschi, A Grejdieru, D Kravcenco, E Prisacari, E Samohvalov, S Samohvalov, N Sceglova, E Panfile, L Cardaniuc, V Corcea, A Feodorovici, V Gaina, L Girbu, P Jimbei, G Balan, I Cardaniuc, I Benesco, V Marian, N Sumarga, B Bozovic, N Bulatovic, P Lakovic, L Music, R Budde, A Wahadat, T Gamela, T Meijers, J P Van Melle, V M Deursen, H J Crijns, S C Bekkers, E C Cheriex, M Gilbers, B L Kietselaer, C Knackstedt, R Lorusso, S Schalla, S A Streukens, S Chamuleau, M-J Cramer, A Teske, T Van der Spoel, A Wind, J Lokhorst, O Liesbek, H Van Heusden, W Tanis, I Van der Bilt, J Vriend, H De Lange-van Bruggen, E Karijodikoro, R Riezebos, E van Dongen, J Schoep, V Stolk, J T Offstad, J O Beitnes, T Helle-Valle, H Skulstad, R Skardal, N Qamar, S Furnaz, B Ahmed, M H Butt, M F Khanzada, T Saghir, A Wahid, T Hryniewiecki, P Szymanski, K Marzec, M Misztal-Ogonowska, W Kosmala, M Przewlocka-Kosmala, A Rojek, K Woznicka, J Zachwyc, A Lisowska, M Kaminska, J D Kasprzak, E Kowalczyk, D F Strzecka, P Wejner-Mik, M Trabulo, P Freitas, S Ranchordas, G Rodrigues, P Pinto, C Queiros, J Azevedo, L Marques, D Seabra, L Branco, M Cruz, A Galrinho, R Moreira, P Rio, A T Timoteo, M Selas, V Carmelo, B Duque Neves, H Pereira, A Guerra, A Marques, I Pintassilgo, M C Tomescu, N-M Trofenciuc, M Andor, A Bordejevic, H S Branea, F Caruntu, L A Velcean, A Mavrea, M F Onel, T Parvanescu, D Pop, A L Pop-Moldovan, M I Puticiu, L Cirin, I M Citu, C A Cotoraci, D Darabantiu, R Farcas, I Marincu, A Ionac, D Cozma, C Mornos, F Goanta, I Popescu, R Beyer, R Mada, R Rancea, R Tomoaia, H Rosianu, C Stanescu, Z Kobalava, J Karaulova, E Kotova, A Milto, A Pisaryuk, N Povalyaev, M Sorokina, J Alrahimi, A Elshiekh, A Jamiel, A Ahmed, N Attia, B Putnikovic, A Dimic, B Ivanovic, S Matic, D Trifunovic, J Petrovic, D Kosevic, I Stojanovic, I Petrovic, P Dabic, P Milojevic, I Srdanovic, S Susak, L Velicki, A Vulin, M Kovacevic, A Redzek, M Stefanovic, T C Yeo, W Kf Kong, K K Poh, I Vilacosta, C Ferrera, C Olmos, M Abd El-Nasser, F Calvo Iglesias, E Blanco-Gonzalez, M Bravo Amaro, E Lopez-Rodriguez, J Lugo Adan, A N Germinas, P Pazos-Lopez, M Pereira Loureiro, M T Perez, S Raposeiras-Roubin, S Rasheed Yas, M-M Suarez-Varela, F Vasallo Vidal, D Garcia-Dorado, N Fernandez-Hidalgo, T Gonzalez-Alujas, J Lozano, O Maisterra, N Pizzi, R Rios, A Bayes-Genis, L Pedro Botet, N Vallejo, C Llibre, L Mateu, R Nunez, D Quesada, E Berastegui, D Bosch Portell, J Aboal Vinas, X Albert Bertran, R Brugada Tarradellas, P Loma-Osorio Ricon, C Tiron de Llano, M A Arnau, A Bel, M Blanes, A Osa, M Anguita, F Carrasco, J C Castillo, J L Zamorano, J L Moya Mur, M Alvaro, C Fernandez-Golfin, J M Monteagudo, E Navas Elorza, M C Farinas Alvarez, J Aguero Balbin, J Zarauza, J F Gutierrez-Diez, C Arminanzas, F Arnaiz de Las Revillas, A Arnaiz Garcia, M Cobo Belaustegui, M Fernandez Sampedro, M Gutierrez Cuadra, L Garcia Cuello, C Gonzalez Rico, R Rodriguez-Alvarez, J Goikoetxea, M Montejo, J M Miro, M Almela, J Ambrosioni, A Moreno, E Quintana, E Sandoval, A Tellez, J M Tolosana, B Vidal, C Falces, D Fuster, C Garcia-de-la-Maria, M Hernandez-Meneses, J Llopis, F Marco, I Ruiz-Zamora, A Bardaji Ruiz, E Sanz Girgas, G Garcia-Pardo, M Guillen Marzo, A Rodriguez Oviedo, A Villares Jimenez, L Abid, R Hammami, S Kammoun, M S Mourali, F Mghaieth Zghal, M Ben Hlima, S Boudiche, S Ouali, L Zakhama, S Antit, I Slama, O Gulel, M Sahin, E Karacaglar, S Kucukoglu, O Cetinarslan, U Y Sinan, U Canpolat, B Mutlu, H Atas, R Dervishova, C Ileri, J Alhashmi, J Tahir, P Zarger, F Baslib, S Woldman, L Menezes, C Primus, R Uppal, I Bvekerwa, B Chandrasekaran, A Kopanska, J Chambers, J Hancock, J Klein, R Rajani, M P Ursi, S Cannata, R Dworakowski, A Fife, J Breeze, M Browne-Morgan, M Gunning, S Streather, F M Asch, M Zemedkun, B Alyavi, J Uzokov, G., Habib, P. A., Erba, B., Iung, E., Donal, B., Cosyn, C., Laroche, B. A., Popescu, B., Prendergast, P., Torno, A., Sadeghpour, L., Oliver, J. -J., Vaskelyte, R., Sow, O., Axler, A. P., Maggioni, P, Lancellotti, P Gale, C, Beleslin, B, Budaj, A, Chioncel, O, Dagres, N, Danchin, N, Emberson, J, Erlinge, D, Glikson, M, Gray, A, Kayikcioglu, M, P Maggioni, A, K Nagy, V, Nedoshivin, A, Petronio, A-S, Roos-Hesselink, J, Wallentin, L, Zeymer, U, Habib, G, Lancellotti, P, Cosyns, B, Donal, E, Erba, P, Iung, B, A Popescu, B, Prendergast, B, Tornos, P, Andarala, M, Berle, C, Brunel-Lebecq, A, Fiorucci, E, Laroche, C, Missiamenou, V, Taylor, C, N Ali Tatar-Chentir, N, Al-Mallah, M, Astrom Aneq, M, Athanassopoulos, G, P Badano, L, Benyoussef, S, Calderon Aranda, E, M Cardim, N, Chan, K-L, Cruz, I, Edvardsen, T, Goliasch, G, Hagendorff, A, Hristova, K, Kamp, O, Kang, D-H, Kong, W, Matskeplishvili, S, Meshaal, M, Mirocevic, M, N Neskovic, A, Pazdernik, M, Plonska-Gosciniak, E, Raissouni, M, Ronderos, R, E Sade, L, Sadeghpour, A, Sambola, A, Sengupta, S, Separovic-Hanzevacki, J, Takeuchi, M, Tucay, E, C Tude Rodrigues, A, Varga, A, Vaskelyte, J, Yamagata, K, Yiangou, K, Zaky, H, Granada, I, Mahia, M, Ressi, S, Nacinovich, F, Iribarren, A, Fernandez Oses, P, Avegliano, G, Filipini, E, Obregon, R, Bangher, M, Dho, J, Cartasegna, L, L Plastino, M, Novas, V, Shigel, C, Reyes, G, De Santos, M, Gastaldello, N, Granillo Fernandez, M, Potito, M, Streitenberger, G, Velazco, P, H Casabé, J, Cortes, C, Guevara, E, Salmo, F, Seijo, M, Weidinger, F, Heger, M, Brooks, R, Stöllberger, C, Ho, C-Y, Perschy, L, Puskas, L, Binder, C, Rosenhek, R, Schneider, M, Winter, M-P, Hoffer, E, Melissopoulou, M, Lecoq, E, Legrand, D, Jacquet, S, Massoz, M, Pierard, L, Marchetta, S, Dulgheru, R, D Emal, C, Oury, C, Droogmans, S, Kerkhove, D, Plein, D, Soens, L, Weytjens, C, Motoc, A, Roosens, B, Lemoine, I, Rodrigus, I, Paelinck, B, Amsel, B, Unger, P, Konopnicki, D, Beauloye, C, Pasquet, A, L Vanoverschelde, J, Pierard, S, Vancraeynest, D, Sinnaeve, F, L Andrade, J, Staszko, K, Dos Santos Monteiro, R, H Miglioranza, M, L Shuha, D, Alcantara, M, Cravo, V, Fazzio, L, Felix, A, Iso, M, Musa, C, P Siciliano, A, Villaca Filho, F, Rodrigues, A, Vilela, F, Braga, J, Silva, R, Rodrigues, D, Silva, L, Morhy, S, Fischer, C, Vieira, M, Afonso, T, Abreu, J, N Falcao, S, A Moises, V, Gouvea, A, J Mancuso, F, C Souza, A, Y Silva, C, João, G, S Abboud, C, Bellio de Mattos Barretto, R, Ramos, A, Arnoni, R, E Assef, J, J Della Togna, D, Le Bihan, D, Miglioli, L, P Romero Oliveira, A, Tadeu Magro Kroll, R, Cortez, D, L Gelape, C, C Peirira Nunes, M D, C De Abreu Ferrari, T, Hay, K, Le, V, Page, M, Poulin, F, Sauve, C, Serri, K, Mercure, C, Beaudoin, J, Pibarot, P, A Sebag, I, G Rudski, L, Ricafort, G, Barsic, B, Krajinovic, V, Vargovic, M, Lovric, D, Reskovic-Luksic, V, Vincelj, J, Jaksic Jurinjak, S, Yiannikourides, V, Ioannides, M, Pofaides, C, Masoura, V, Pudich, J, Linhart, A, Siranec, M, Marek, J, Blechova, K, Kamenik, M, Pelouch, R, Coufal, Z, Mikulica, M, Griva, M, Jancova, E, Mikulcova, M, Taborsky, M, Precek, J, Jecmenova, M, Latal, J, Widimsky, J, Butta, T, Machacek, S, Vancata, R, Spinar, J, Holicka, M, Pow Chon Long, F, Anzules, N, Bajana Carpio, A, Largacha, G, Penaherrera, E, Moreira, D, Mahfouz, E, Elsafty, E, Soliman, A, Zayed, Y, Aboulenein, J, Abdel-Hay, M, Almaghraby, A, Abdelnaby, M, Ahmed, M, Hammad, B, Saleh, Y, Zahran, H, Elgebaly, O, Saad, A, Ali, M, Zeid, A, El Sharkawy, R, Al Kholy, A, Doss, R, Osama, D, Rizk, H, Elmogy, A, Mishriky, M, Assayag, P, El Hatimi, S, Hubert, S, Casalta, J-P, Gouriet, F, Arregle, F, Cammilleri, S, Tessonnier, L, Riberi, A, Botelho-Nevers, E, Gagneux-Brunon, A, Pierrard, R, Tulane, C, Campisi, S, Fuzellier, J-F, Detoc, M, Mehalla, T, Boutoille, D, S Lecompte, A, Lefebvre, M, Pattier, S, Al Habash, O, Asseray-Madani, N, Biron, C, Brochard, J, Caillon, J, Cueff, C, Le Tourneau, T, Lecomte, R, M Magali Michel, M, Orain, J, Delarue, S, Le Bras, M, Faucher, J-F, Aboyans, V, Beeharry, A, Durox, H, Lacoste, M, Magne, J, Mohty, D, David, A, Pradel, V, Sierra, V, Neykova, A, Bettayeb, B, Elkentaoui, S, Tzvetkov, B, Landry, G, Strady, C, Ainine, K, Baumard, S, Brasselet, C, Tassigny, C, Valente-Pires, V, Lefranc, M, Hoen, B, Lefevre, B, Curlier, E, Callier, C, Fourcade, N, Jobic, Y, Ansard, S, Le Berre, R, Le Ven, F, Pouliquen, M-C, Prat, G, Le Roux, P, Bouchart, F, Savoure, A, Alarcon, C, Chapuzet, C, Gueit, I, Tribouilloy, C, Bohbot, Y, Peugnet, F, Gun, M, Duval, X, Lescure, X, Ilic-Habensus, E, Sadoul, N, Selton-Suty, C, Alla, F, Goehringer, F, Huttin, O, Chevalier, E, Garcia, R, Le Marcis, V, Tattevin, P, Flecher, E, Revest, M, Chirouze, C, Bouiller, K, Hustache-Mathieu, L, Klopfenstein, T, Moreau, J, Fournier, D, Brunel, A-S, Lim, P, Oliver, L, Ternacle, J, Moussafeur, A, Chavanet, P, Piroth, L, Salmon-Rousseau, A, Buisson, M, Mahy, S, Martins, C, Gohier, S, Axler, O, Baumann, F, Lebras, S, Piper, C, Guckel, D, Börgermann, J, Horstkotte, D, Winkelmann, E, Brockmeier, B, Grey, D, Nickenig, G, Schueler, R, Öztürk, C, Stöhr, E, Hamm, C, Walther, T, Brandt, R, Frühauf, A-C, T Hartung, C, Hellner, C, Wild, C, Becker, M, Hamada, S, Kaestner, W, Stangl, K, Knebel, F, Baldenhofer, G, Brecht, A, Dreger, H, Isner, C, Pfafflin, F, Stegemann, M, Zahn, R, Fraiture, B, Kilkowski, C, Karcher, A-K, Klinger, S, Tolksdorf, H, Tousoulis, D, Aggeli, C, Sideris, S, Venieri, E, Sarri, G, Tsiapras, D, Armenis, I, Koutsiari, A, Floros, G, Grassos, C, Dragasis, S, Rallidis, L, Varlamos, C, Michalis, L, Naka, K, Bechlioulis, A, Kotsia, A, Lakkas, L, Pappas, K, Papadopoulos, C, Kiokas, S, Lioni, A, Misailidou, S, Barbetseas, J, Bonou, M, Kapelios, C, Tomprou, I, Zerva, K, Manolis, A, Hamodraka, E, Athanasiou, D, Haralambidis, G, Samaras, H, Poulimenos, L, Nagy, A, Bartykowszki, A, Gara, E, Mungulmare, K, Kasliwal, R, Bansal, M, Ranjan, S, Bhan, A, Kyavar, M, Maleki, M, Noohi Bezanjani, F, Alizadehasl, A, Boudagh, S, Ghavidel, A, Moradnejad, P, R Pasha, H, Ghadrdoost, B, Gilon, D, Strahilevitz, J, Wanounou, M, Israel, S, D'Agostino, C, Colonna, P, De Michele, L, Fumarola, F, Stante, M, Marchionni, N, Scheggi, V, Alterini, B, Del Pace, S, Stefano, P, Sparano, C, Ruozi, N, Tenaglia, R, Muraru, D, Limbruno, U, Cresti, A, Baratta, P, Solari, M, Giannattasio, C, Moreo, A, De Chiara, B, Lopez Montero, B, Musca, F, A Orcese, C, Panzeri, F, Spano, F, F Russo, C, Alfieri, O, DE BONIS, Michele, Chiappetta, S, Del Forno, B, Ripa, M, Scarpellini, P, Tassan Din, C, Castiglioni, B, Pasciuta, R, Carletti, S, Ferrara, D, Guffanti, M, Iaci, G, Lapenna, E, Nisi, T, Oltolini, C, Busnardo, E, Pajoro, U, Agricola, E, Meneghin, R, Schiavi, D, Piscione, F, Citro, R, M Benvenga, R, Greco, L, Soriente, L, Radano, I, Prota, C, Bellino, M, Di Vece, D, Santini, F, Salsano, A, M Olivieri, G, Turrini, F, Messora, R, Tondi, S, Olaru, A, Agnoletto, V, Grassi, L, Leonardi, C, Sansoni, S, Del Ponte, S, M Actis Dato, G, De Martino, A, Ohte, N, Kikuchi, S, Wakami, K, Aonuma, K, Seo, Y, Ishizu, T, Machino-Ohtsuka, T, Yamamoto, M, Iida, N, Nakajima, H, Nakagawa, Y, Izumi, C, Amano, M, Miyake, M, Takahashi, K, Shiojima, I, Miyasaka, Y, Maeba, H, Suwa, Y, Taniguchi, N, Tsujimoto, S, Kitai, T, Ota, M, Yuda, S, Sasaki, S, Hagiwara, N, Yamazaki, K, Ashihara, K, Arai, K, Saitou, C, Saitou, S, Suzuki, G, Shibata, Y, Watanabe, N, Nishino, S, Ashikaga, K, Kuriyama, N, Mahara, K, Okubo, T, Fujimaki, H, Shitan, H, Yamamoto, H, Abe, K, Terada, M, Takanashi, S, Sata, M, Yamada, H, Kusunose, K, Saijo, Y, Seno, H, Yuichiro, O, Onishi, T, Sera, F, Nakatani, S, Mizuno, H, Sengoku, K, W Park, S, Eun Kyoung, K, Ga Yeon, L, Hwang, J-W, Jin-Oh, C, Park, S-J, Sang-Chol, L, Sung-A, C, Y Jang, S, Heo, R, Lee, S, Song, J-M, Jung, E, Plisiene, J, Dambrauskaite, A, Gruodyte, G, Jonkaitiene, R, Mizariene, V, Atkocaityte, J, Zvirblyte, R, Sow, R, Codreanu, A, Staub, T, Michaux, C, L De la Vega, E C, Jacobs-Orazi, L, Mallia Azzopardi, C, G Xuereb, R, Piscopo, T, Farrugia, J, Fenech, M, Pllaha, E, Vella, C, Borg, D, Casha, R, Grib, L, Raevschi, E, Grejdieru, A, Kravcenco, D, Prisacari, E, Samohvalov, E, Samohvalov, S, Sceglova, N, Panfile, E, Cardaniuc, L, Corcea, V, Feodorovici, A, Gaina, V, Girbu, L, Jimbei, P, Balan, G, Cardaniuc, I, Benesco, I, Marian, V, Sumarga, N, Bozovic, B, Bulatovic, N, Lakovic, P, Music, L, Budde, R, Wahadat, A, Gamela, T, Meijers, T, P Van Melle, J, M Deursen, V, J Crijns, H, C Bekkers, S, C Cheriex, E, Gilbers, M, L Kietselaer, B, Knackstedt, C, Lorusso, R, Schalla, S, A Streukens, S, Chamuleau, S, Cramer, M-J, Teske, A, Van der Spoel, T, Wind, A, Lokhorst, J, Liesbek, O, Van Heusden, H, Tanis, W, Van der Bilt, I, Vriend, J, De Lange-van Bruggen, H, Karijodikoro, E, Riezebos, R, van Dongen, E, Schoep, J, Stolk, V, T Offstad, J, O Beitnes, J, Helle-Valle, T, Skulstad, H, Skardal, R, Qamar, N, Furnaz, S, Ahmed, B, H Butt, M, F Khanzada, M, Saghir, T, Wahid, A, Hryniewiecki, T, Szymanski, P, Marzec, K, Misztal-Ogonowska, M, Kosmala, W, Przewlocka-Kosmala, M, Rojek, A, Woznicka, K, Zachwyc, J, Lisowska, A, Kaminska, M, D Kasprzak, J, Kowalczyk, E, F Strzecka, D, Wejner-Mik, P, Trabulo, M, Freitas, P, Ranchordas, S, Rodrigues, G, Pinto, P, Queiros, C, Azevedo, J, Marques, L, Seabra, D, Branco, L, Cruz, M, Galrinho, A, Moreira, R, Rio, P, T Timoteo, A, Selas, M, Carmelo, V, Duque Neves, B, Pereira, H, Guerra, A, Marques, A, Pintassilgo, I, C Tomescu, M, Trofenciuc, N-M, Andor, M, Bordejevic, A, S Branea, H, Caruntu, F, A Velcean, L, Mavrea, A, F Onel, M, Parvanescu, T, Pop, D, L Pop-Moldovan, A, I Puticiu, M, Cirin, L, M Citu, I, A Cotoraci, C, Darabantiu, D, Farcas, R, Marincu, I, Ionac, A, Cozma, D, Mornos, C, Goanta, F, Popescu, I, Beyer, R, Mada, R, Rancea, R, Tomoaia, R, Rosianu, H, Stanescu, C, Kobalava, Z, Karaulova, J, Kotova, E, Milto, A, Pisaryuk, A, Povalyaev, N, Sorokina, M, Alrahimi, J, Elshiekh, A, Jamiel, A, Ahmed, A, Attia, N, Putnikovic, B, Dimic, A, Ivanovic, B, Matic, S, Trifunovic, D, Petrovic, J, Kosevic, D, Stojanovic, I, Petrovic, I, Dabic, P, Milojevic, P, Srdanovic, I, Susak, S, Velicki, L, Vulin, A, Kovacevic, M, Redzek, A, Stefanovic, M, C Yeo, T, Kf Kong, W, K Poh, K, Vilacosta, I, Ferrera, C, Olmos, C, Abd El-Nasser, M, Calvo Iglesias, F, Blanco-Gonzalez, E, Bravo Amaro, M, Lopez-Rodriguez, E, Lugo Adan, J, N Germinas, A, Pazos-Lopez, P, Pereira Loureiro, M, T Perez, M, Raposeiras-Roubin, S, Rasheed Yas, S, Suarez-Varela, M-M, Vasallo Vidal, F, Garcia-Dorado, D, Fernandez-Hidalgo, N, Gonzalez-Alujas, T, Lozano, J, Maisterra, O, Pizzi, N, Rios, R, Bayes-Genis, A, Pedro Botet, L, Vallejo, N, Llibre, C, Mateu, L, Nunez, R, Quesada, D, Berastegui, E, Bosch Portell, D, Aboal Vinas, J, Albert Bertran, X, Brugada Tarradellas, R, Loma-Osorio Ricon, P, Tiron de Llano, C, A Arnau, M, Bel, A, Blanes, M, Osa, A, Anguita, M, Carrasco, F, C Castillo, J, L Zamorano, J, L Moya Mur, J, Alvaro, M, Fernandez-Golfin, C, M Monteagudo, J, Navas Elorza, E, C Farinas Alvarez, M, Aguero Balbin, J, Zarauza, J, F Gutierrez-Diez, J, Arminanzas, C, Arnaiz de Las Revillas, F, Arnaiz Garcia, A, Cobo Belaustegui, M, Fernandez Sampedro, M, Gutierrez Cuadra, M, Garcia Cuello, L, Gonzalez Rico, C, Rodriguez-Alvarez, R, Goikoetxea, J, Montejo, M, M Miro, J, Almela, M, Ambrosioni, J, Moreno, A, Quintana, E, Sandoval, E, Tellez, A, M Tolosana, J, Vidal, B, Falces, C, Fuster, D, Garcia-de-la-Maria, C, Hernandez-Meneses, M, Llopis, J, Marco, F, Ruiz-Zamora, I, Bardaji Ruiz, A, Sanz Girgas, E, Garcia-Pardo, G, Guillen Marzo, M, Rodriguez Oviedo, A, Villares Jimenez, A, Abid, L, Hammami, R, Kammoun, S, S Mourali, M, Mghaieth Zghal, F, Ben Hlima, M, Boudiche, S, Ouali, S, Zakhama, L, Antit, S, Slama, I, Gulel, O, Sahin, M, Karacaglar, E, Kucukoglu, S, Cetinarslan, O, Y Sinan, U, Canpolat, U, Mutlu, B, Atas, H, Dervishova, R, Ileri, C, Alhashmi, J, Tahir, J, Zarger, P, Baslib, F, Woldman, S, Menezes, L, Primus, C, Uppal, R, Bvekerwa, I, Chandrasekaran, B, Kopanska, A, Chambers, J, Hancock, J, Klein, J, Rajani, R, P Ursi, M, Cannata, S, Dworakowski, R, Fife, A, Breeze, J, Browne-Morgan, M, Gunning, M, Streather, S, M Asch, F, Zemedkun, M, Alyavi, B, Uzokov, J, Hôpital de la Timone [CHU - APHM] (TIMONE), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Groningen [Groningen] (UMCG), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Université de Médecine Carol Davila, Guy's and St Thomas' Hospital [London], CHU Henri Mondor, Centre Hospitalier Universitaire de Liège (CHU-Liège), AstraZeneca, Bayer, Edwards Lifesciences, Servier, Abbott Vascular Int., Amgen Cardiovascular, Pfizer Alliance, Daiichi Sankyo Europe GmbH, Alliance Daiichi Sankyo Europe GmbH, Gedeon Richter Plc., Menarini Int. Op., Vifor, Boehringer Ingelheim, Boston Scientific Corporation, Bristol-Myers Squibb, Eli Lilly and Company, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de pathologies cardiovasculaires intensives, UCL - (SLuc) Service de soins intensifs, Service de cardiologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Oxford University Hospitals NHS Trust, University of Oxford [Oxford], Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Bordeaux (UB), Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri] (ANMCO Research Center), Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Service de cardiologie [Liège], CHU de Liège-Domaine Universitaire du Sart Tilman, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Exeter, Instituto Nacional de Tecnología Agropecuaria, Pergamino, Argentina, Laboratory of In Vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel (VUB), Centre National de la Recherche Scientifique (CNRS), Division of Engineering and Applied Science, California Institute of Technology, California Institute of Technology (CALTECH), Departamento de Biologia de la Reproduccion, Universidad Autónoma Metropolitana Iztapalapa (UAMI), Universidade Federal de Itajubá, Departamento de Física [Coimbra] (DFC), Universidade de Coimbra [Coimbra], Section of Internal Medicine and Endocrine and Metabolic Sciences, Università degli Studi di Perugia (UNIPG), LIP-Coimbra & Department of Physics of the University of Coimbra, Service Hospitalier Frédéric Joliot (SHFJ), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Quebec Heart Institute/Laval Hospital, Université Laval [Québec] (ULaval)-Quebec Heart Institute, Institut Lavoisier de Versailles (ILV), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), CHU Saint-Etienne, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de bactériologie et hygiène hospitalière [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut du thorax, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies infectieuses et tropicales [CHU Limoges], CHU Limoges, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre Hospitalier Universitaire de Reims (CHU Reims), Anesthésie et réanimation en chirurgie cardiaque [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Normandie Université (NU), Service des maladies infectieuses et tropicales [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Cardiology [Ospedali del Tigullio], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Cardiologie [CHRU Nancy], Service des maladies infectieuses et réanimation médicale, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Service de chirurgie thoracique cardiaque et vasculaire [Rennes], Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institució Catalana de Recerca i Estudis Avançats (ICREA), Institute for Advanced Studies in Basic Sciences, affiliation inconnue, Dipartamento di Fisica 'E.R. Caianiello', Università degli Studi di Salerno (UNISA), The University of Tokyo, Northern Research Station, Forestry Commission, University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Instituto de Plasmas e Fusão Nuclear [Lisboa] (IPFN), Instituto Superior Técnico, Universidade Técnica de Lisboa (IST), Instituto de Investigaciones Marinas (CSIC), Faculté des Sciences Pharmaceutiques, EA 4529, Laboratoire de Biochimie, Université Paris-Sud - Paris 11 (UP11), Istituto di Virologia Vegetale, Università degli studi di Torino (UNITO), Universidad Nacional Autónoma de México (UNAM), Service de Chirurgie Cardiovasculaire, University Hospital of Cruces, Geneva University Hospital (HUG), Institut Jean Le Rond d'Alembert (DALEMBERT), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Preventive Medicine Unit, University Hospital Joan XXIII, IISPV, Rovira and Virgili University, Popescu, B, Maggioni, A, Gale, C, Nagy, V, Petronio, A, Ali Tatar-Chentir, N, Badano, L, Cardim, N, Chan, K, Kang, D, Neskovic, A, Sade, L, Tude Rodrigues, A, Plastino, M, Casabe, J, Stollberger, C, Ho, C, Winter, M, Emal, C, Vanoverschelde, J, Andrade, J, Miglioranza, M, Shuha, D, Siciliano, A, Falcao, S, Moises, V, Mancuso, F, Souza, A, Silva, C, Joao, G, Abboud, C, Assef, J, Della Togna, D, Romero Oliveira, A, Gelape, C, Peirira Nunes, M, De Abreu Ferrari, T, Sebag, I, Rudski, L, Casalta, J, Fuzellier, J, Lecompte, A, Magali Michel, M, Faucher, J, Pouliquen, M, Brunel, A, Borgermann, J, Ozturk, C, Stohr, E, Fruhauf, A, Hartung, C, Karcher, A, Pasha, H, Orcese, C, Russo, C, De Bonis, M, Benvenga, R, Olivieri, G, Actis Dato, G, Park, S, Hwang, J, Jang, S, Song, J, De la Vega, E, Xuereb, R, Van Melle, J, Deursen, V, Crijns, H, Bekkers, S, Cheriex, E, Kietselaer, B, Streukens, S, Cramer, M, Offstad, J, Beitnes, J, Butt, M, Khanzada, M, Kasprzak, J, Strzecka, D, Timoteo, A, Tomescu, M, Trofenciuc, N, Branea, H, Velcean, L, Onel, M, Pop-Moldovan, A, Puticiu, M, Citu, I, Cotoraci, C, Yeo, T, Poh, K, Germinas, A, Perez, M, Suarez-Varela, M, Arnau, M, Castillo, J, Zamorano, J, Moya Mur, J, Monteagudo, J, Farinas Alvarez, M, Gutierrez-Diez, J, Miro, J, Tolosana, J, Mourali, M, Yasar, U, Ursi, M, Asch, F, Clinical sciences, Cardio-vascular diseases, Cardiology, Medical Imaging, Cardiovascular Centre (CVC), Service de médecine nucléaire [Marseille], Imagerie MOléculaire pour applications THéranostiques personnalisées (IMOTHEP), Institut FRESNEL (FRESNEL), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), MGSOG Scientific staff, MUMC+: MA Cardiologie (9), Cardiologie, RS: Carim - H01 Clinical atrial fibrillation, RS: CARIM - R2.01 - Clinical atrial fibrillation, RS: CARIM - R3.11 - Imaging, Promovendi CD, Fysiologie, MUMC+: MA Med Staf Artsass CTC (9), RS: CARIM - R1.06 - Genetic Epidemiology and Genomics of cardiovascular diseases, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H02 Cardiomyopathy, RS: CARIM - R2.02 - Cardiomyopathy, CTC, MUMC+: MA Med Staf Spec CTC (9), RS: Carim - V04 Surgical intervention, RS: CARIM - R2.12 - Surgical intervention, RS: FdR IC Aansprakelijkheid, Graduate School, ACS - Heart failure & arrhythmias, Radiotherapy, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, and ACS - Atherosclerosis & ischemic syndromes

Subjects
Male, SURGERY, Embolism, Infective endocarditi, Infective endocarditis, Registry, Valve disease, 030204 cardiovascular system & hematology, 0302 clinical medicine, Africa, Northern, Positron Emission Tomography Computed Tomography, 030212 general & internal medicine, Hospital Mortality, Prospective Studies, Registries, Prospective cohort study, Abscess, Aged, 80 and over, medicine.diagnostic_test, Middle Aged, Staphylococcal Infections, 3. Good health, Cardiac surgery, Community-Acquired Infections, Europe, Treatment Outcome, Positron emission tomography, Echocardiography, Heart Valve Prosthesis, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Female, ECHOCARDIOGRAPHY, Cardiology and Cardiovascular Medicine, Adult, medicine.medical_specialty, Asia, Prosthesis-Related Infections, DIAGNOSIS, 03 medical and health sciences, Fluorodeoxyglucose F18, Internal medicine, Streptococcal Infections, medicine, MANAGEMENT, Journal Article, Humans, Aged, business.industry, EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY, Endocarditis, Bacterial, South America, medicine.disease, Heart failure, Etiology, Radiopharmaceuticals, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Enterococcus
Abstract

Aims The EURO-ENDO registry aimed to study the management and outcomes of patients with infective endocarditis (IE). Methods and results Prospective cohort of 3116 adult patients (2470 from Europe, 646 from non-ESC countries), admitted to 156 hospitals in 40 countries between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic criteria. Clinical, biological, microbiological, and imaging [echocardiography, computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)] data were collected. Infective endocarditis was native (NVE) in 1764 (56.6%) patients, prosthetic (PVIE) in 939 (30.1%), and device-related (CDRIE) in 308 (9.9%). Infective endocarditis was community-acquired in 2046 (65.66%) patients. Microorganisms involved were staphylococci in 1085 (44.1%) patients, oral streptococci in 304 (12.3%), enterococci in 390 (15.8%), and Streptococcus gallolyticus in 162 (6.6%). 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed in 518 (16.6%) patients and presented with cardiac uptake (major criterion) in 222 (42.9%) patients, with a better sensitivity in PVIE (66.8%) than in NVE (28.0%) and CDRIE (16.3%). Embolic events occurred in 20.6% of patients, and were significantly associated with tricuspid or pulmonary IE, presence of a vegetation and Staphylococcus aureus IE. According to ESC guidelines, cardiac surgery was indicated in 2160 (69.3%) patients, but finally performed in only 1596 (73.9%) of them. In-hospital death occurred in 532 (17.1%) patients and was more frequent in PVIE. Independent predictors of mortality were Charlson index, creatinine > 2 mg/dL, congestive heart failure, vegetation length > 10 mm, cerebral complications, abscess, and failure to undertake surgery when indicated. Conclusion Infective endocarditis is still a life-threatening disease with frequent lethal outcome despite profound changes in its clinical, microbiological, imaging, and therapeutic profiles.

Published
2019

293. The impact of the use of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patients

Author

Almaghraby, A. Abdallah, Abdelnabi, M., Oz, T. Kemaloglu, Elgowelly, M., Yehia Saleh, Badran, H., Almaghraby, A. Abdallah, Elgowelly, M. Alexandria Univ, Alexandria, Egypt, Abdelnabi, M. Med Res Inst, Alexandria, Egypt, Oz, T. Kemaloglu Medipol Univ, Caml Hosp, Istanbul, Turkey, Saleh, Y. Michigan State Univ, E Lansing, MI 48824 USA, and Badran, H. Ain Shams Univ, Cairo, Egypt

Subjects
Angiotensin II Receptor Blockers (ARBs), cardiovascular diseases, HFrEF, Sacubitril/Valsartan
Abstract

WOS: 000468990702307 Background: Sacubitril/valsartan is a guideline-recommended alternative drug to Angiotensin-Converting enzyme inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) to reduce morbidity and mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF). Recent guideline update specifically advises switching symptomatic HFrEF patients to sacubitril/valsartan for further reduction of morbidity and mortality. Purpose: The aim of the work was to demonstrate the clinical effects of the use of sacubitril/valsartan instead of the conventional ACEIs or ARBs in HFrEF patients. Methods: A total number of 23 patients with miscellaneous causes of heart failure (14 patients had ischemic etiology, 8 patients had dilated cardiomyopathy and 1 patient had peripartum cardiomyopathy) presented in the setting of heart failure (NYHA III-IV) with normal creatinine clearance. Through clinical examination and baseline 2D transthoracic echocardiography (TTE) was done with an emphasis on left ventricular ejection fraction (LVEF) and end diastolic volume (EDV). All patients received sacubitril/valsartan instead of ACEs inhibitors or ARBs together with beta-blockers, diuretics and Mineralocorticoid antagonists when indicated. Follow-up after 6 months was done to assess patient clinical status as regards heart failure symptoms and follow up TTE as regards LVEF and EDV. Results: The mean age of the patients was 46.89 ± 15.4 years, 14 patients (60.87 %) had a baseline NYHA III while 9 patients (39.13%) had NYHA IV. Mean baseline LVEF and EDV were 27.3% ± 8 and 277.11 ± 57.67 ml respectively. At 6 months follow-up, 21 patients (91.3%) had NYHA I while 2 patients had NYHA II (8.7 %), mean LVEF and EDV were 49.05% ± 10.27 and 202.79 ± 64.86 ml respectively. (P

Published
2019

294. Study of in vitro and in vivo genotoxic effects of air pollution fine (PM2.5-0.18) and quasi-ultrafine (PM0.18) particles on lung models.

Author

Platel, A., Privat, K., Talahari, S., Delobel, A., Dourdin, G., Gateau, E., Simar, S., Saleh, Y., Sotty, J., Antherieu, S., Canivet, L., Alleman, L.-Y., Perdrix, E., Garçon, G., Denayer, F.O., Lo Guidice, J.M., and Nesslany, F.

Abstract

• PM 2.5-0.18 and PM 0.18 induced primary DNA damage but no chromosome aberrations in immortalized cells. • PM 2.5 and PM 2.5-0.18 are devoid of in vitro genotoxic effect in NHBE primary cells. • PM 2.5 and PM 2.5-0.18 exhibit no in vivo genotoxic/mutagenic activity in our tested conditions. • Development of standardized methodologies for assessing the in vitro genotoxicity of PM is needed. • Epigenetics possibly implicated in pulmonary carcinogenesis should be investigated. Air pollution and particulate matter (PM) are classified as carcinogenic to humans. Pollutants evidence for public health concern include coarse (PM 10) and fine (PM 2.5) particles. However, ultrafine particles (PM 0.1) are assumed to be more toxic than larger particles, but data are still needed to better understand their mechanism of action. In this context, the aim of our work was to investigate the in vitro and in vivo genotoxic potential of fine (PM 2.5-018) and quasi ultra-fine (PM 0.18) particles from an urban-industrial area (Dunkirk, France) by using comet, micronucleus and/or gene mutation assays. In vitro assessment was performed with 2 lung immortalized cell lines (BEAS-2B and NCI-H292) and primary normal human bronchial epithelial cells (NHBE) grown at the air-liquid interface or in submerged conditions (5 µg PM/cm2). For in vivo assessment, tests were performed after acute (24 h, 100 µg PM/animal), subacute (1 month, 10 µg PM/animal) and subchronic (3 months, 10 µg PM/animal) intranasal exposure of BALB/c mice. In vitro , our results show that PM 2.5-018 and PM 0.18 induced primary DNA damage but no chromosomal aberrations in immortalized cells. Negative results were noted in primary cells for both endpoints. In vivo assays revealed that PM 2.5-018 and PM 0.18 induced no significant increases in DNA primary damage, chromosomal aberrations or gene mutations, whatever the duration of exposure. This investigation provides initial answers regarding the in vitro and in vivo genotoxic mode of action of PM 2.5-018 and PM 0.18 at moderate doses and highlights the need to develop standardized specific methodologies for assessing the genotoxicity of PM. Moreover, other mechanisms possibly implicated in pulmonary carcinogenesis, e.g. epigenetics, should be investigated. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

295. Toxicological effects of ambient fine (PM2.5-0.18) and ultrafine (PM0.18) particles in healthy and diseased 3D organo-typic mucocilary-phenotype models.

Author

Sotty, J., Garçon, G., Denayer, F.-O., Alleman, L.-Y., Saleh, Y., Perdrix, E., Riffault, V., Dubot, P., Lo-Guidice, J.-M., and Canivet, L.

Subjects
*PARTICULATE matter, *OBSTRUCTIVE lung diseases, *HISTONE acetylation, *PHYSIOLOGICAL control systems, *CELL anatomy, *ENDOTOXINS
Abstract

The knowledge of the underlying mechanisms by which particulate matter (PM) exerts its health effects is still incomplete since it may trigger various symptoms as some persons may be more susceptible than others. Detailed studies realized in more relevant in vitro models are highly needed. Healthy normal human bronchial epithelial (NHBE), asthma-diseased human bronchial epithelial (DHBE), and COPD-DHBE cells, differentiated at the air-liquid interface, were acutely or repeatedly exposed to fine (i.e., PM 2.5-0.18 , also called FP) and quasi-ultrafine (i.e., PM 0.18 , also called UFP) particles. Immunofluorescence labelling of pan-cytokeratin, MUC5AC, and ZO-1 confirmed their specific cell-types. Baselines of the inflammatory mediators secreted by all the cells were quite similar. Slight changes of TNFα, IL-1β, IL-6, IL-8, GM-CSF, MCP-1, and/or TGFα, and of H3K9 histone acetylation supported a higher inflammatory response of asthma- and especially COPD-DHBE cells, after exposure to FP and especially UFP. At baseline, 35 differentially expressed genes (DEG) in asthma-DHBE, and 23 DEG in COPD-DHBE, compared to NHBE cells, were reported. They were involved in biological processes implicated in the development of asthma and COPD diseases, such as cellular process (e.g., PLA2G4C, NLRP1, S100A5, MUC1), biological regulation (e.g., CCNE1), developmental process (e.g., WNT10B), and cell component organization and synthesis (e.g., KRT34 , COL6A1 , COL6A2). In all the FP or UFP-exposed cell models, DEG were also functionally annotated to the chemical metabolic process (e.g., CYP1A1 , CYP1B1 , CYP1A2) and inflammatory response (e.g., EREG). Another DEG, FGF-1 , was only down-regulated in asthma and specially COPD-DHBE cells repeatedly exposed. While RAB37 could help to counteract the down-regulation of FGF-1 in asthma-DHBE cells, the deregulation of FGR, WNT7B, VIPR1 , and PPARGC1A could dramatically contribute to make it worse in COPD-DHBE cells. Taken together, these data contributed to support the highest effects of UFP versus FP and highest sensitivity of asthma- and notably COPD-DHBE versus NHBE cells. • Innovative healthy and diseased 3D organo-typic mucocilary-phenotype models. • Experimental strategy of repeated exposures to ambient fine and ultrafine particles. • Better knowledge on the adverse effects of ambient fine and ultrafine particles. • Highest adverse effects of ultrafine vs fine particles. • Highest responsiveness of diseased vs healthy cell models. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

296. Association of metabolic obesity phenotypes with risk of overall and site-specific cancers: a systematic review and meta-analysis of cohort studies.

Author

Mahamat-Saleh Y, Aune D, Freisling H, Hardikar S, Jaafar R, Rinaldi S, Gunter MJ, and Dossus L

Subjects
Female, Humans, Male, Adiposity, Cohort Studies, Phenotype, Risk Factors, Neoplasms epidemiology, Neoplasms etiology, Obesity complications, Obesity metabolism
Abstract

Background: Adiposity is a known risk factor for certain cancers; however, it is not clear whether the risk of cancer differs between individuals with high adiposity but different metabolic health status. The aim of this systematic literature review and meta-analysis of cohort studies was to evaluate associations between metabolic obesity phenotypes and overall and site-specific cancer risk., Methods: PubMed and Embase databases were used to identify relevant cohort studies up to the 6th of June 2023. Random-effects models were used to estimate summary relative risks (SRRs) and 95% confidence intervals (CIs) for the association between metabolic obesity phenotypes and cancer risk. Certainty of evidence was assessed using the Cochrane methods and the GRADE tool. This study is registered with PROSPERO, number CRD42024549511., Results: A total of 15,556 records were screened, and 31 publications covering 15 unique cohort studies were included in this analysis. Of these studies, 22 were evaluated as being at low risk of bias and 9 at moderate risk of bias. Compared to metabolically healthy normal-weight individuals (MHNW), metabolically unhealthy overweight/obese (MUOW/OB) individuals had a higher risk of overall (SRR = 1.21, 95% CI = 1.02-1.44, n = 3 studies, high certainty) and obesity-related cancers (SRR = 1.42, 95% CI = 1.15-1.74, n = 3, very low certainty). Specifically, MUOW/OB individuals were at higher risk of cancers of the postmenopausal breast (SRR = 1.32, 95% CI = 1.17-1.48, n = 7, low certainty), colorectum (SRR = 1.24, 95% CI = 1.16-1.31, n = 6, moderate certainty), endometrium (SRR = 2.31, 95% CI = 2.08-2.57, n = 4, high certainty), thyroid (SRR = 1.42, 95% CI = 1.29-1.57, n = 4, moderate certainty), kidney (SRR = 1.71, 95% CI = 1.40-2.10, n = 3, low certainty), pancreas (SRR = 1.35, 95% CI = 1.24-1.47, n = 3, high certainty), liver (SRR = 1.81, 95% CI = 1.36-2.42, n = 2, moderate certainty), gallbladder (SRR = 1.42, 95% CI = 1.17-1.73, n = 2, high certainty), bladder (SRR = 1.36, 95% CI = 1.19-1.56, n = 2, moderate certainty), and stomach (SRR = 1.50, 95% CI = 1.12-2.01, n = 2, high certainty). In addition, we found elevated risks of most of these cancers among individuals classified as MUNW and MHOW/OB phenotypes compared to those with MHNW phenotype. Our stratified analyses according to metabolic obesity phenotypes suggested that the elevated risks of some cancers were stronger in individuals with MUOW/OB versus those with MHOW/OB or MUNW phenotypes., Conclusion: These findings suggest that both higher adiposity and metabolic dysfunction were independently associated with increased risk of several cancers, with the strongest associations generally observed among those with both metabolic dysfunction and obesity., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

299. The Impact of Bariatric Surgery on Weight Reduction and the Resolution of Comorbidities in Older Geriatric Populations of Saudi Arabia: A Retrospective Study.

Author

Alamri AM, Alsareii SA, Isaway NA, Alshaiban SH, Alyami SY, and Alsaid MT

Abstract

Background Obesity is a significant health concern among older adults, leading to various comorbidities and reduced quality of life. Bariatric surgery (BS) has emerged as a potential intervention, but its efficacy in geriatric populations, particularly in Saudi Arabia, is not well-established. Aims This retrospective study aims to evaluate the impact of BS on weight reduction and comorbidity resolution in Saudi Arabian geriatric populations. Methods A retrospective cohort study was conducted at King Khalid Hospital, Saudi Arabia, involving geriatric patients aged 60 and above who underwent BS between January 2018 and December 2022. Data were collected from medical records and analyzed using descriptive statistics, chi-square tests, t-tests, and multivariate regression analysis. Results The study included a total of 26 patients with a mean age of 64 years. Of these, 18 (69.3%) were females, while eight (30.7%) were males, and 23 (87%) underwent sleeve gastrectomy (SG), while three (13%) had Roux-en-Y gastric bypass (RYGB). Preoperative comorbidities majorly included diabetes (17, 35.42%), hypertension (11, 22.92%), and anemia (four, 8.33%). The average body mass index (BMI) of the patients decreased significantly from 45.12 to 37.29 at three months and further to 31.36 at six months post surgery. Total weight loss (TWL) was 19.92% at three months and 35.15% at six months, while the percentage of excess weight loss (%EWL) was 33.42% at three months and 57.85% at six months. Results also showed a significant reduction in the number of comorbidities postoperatively. A significant association with gender, preoperative weight, and preoperative height at three and six months and a significant association with preoperative BMI and comorbidity status at six months were recorded. Conclusion The study suggests that bariatric surgery is effective in achieving significant weight loss and improving comorbidities in geriatric patients. Few demographic and clinical features affect the outcome of the weight loss., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. The Research Ethics Committee at Najran University (NU), Najran, Saudi Arabia, issued approval 202405-076-020754-047551. Dear Dr. Abdulrahman Manaa Alamri, The Najran University (NU) Research Ethics Committee has recently reviewed your request for ethical approval for the project outlined below. Your proposal is now deemed to meet the requirements of the National Committee for Bioethics at King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia, and full approval has been granted. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Alamri et al.)

Published
2024
Full Text
View/download PDF

300. Association of body shape phenotypes and body fat distribution indexes with inflammatory biomarkers in the European Prospective Investigation into Cancer and Nutrition (EPIC) and UK Biobank.

Author

González-Gil EM, Peruchet-Noray L, Sedlmeier AM, Christakoudi S, Biessy C, Navionis AS, Mahamat-Saleh Y, Jaafar RF, Baurecht H, Guevara M, Etxezarreta PA, Verschuren WMM, Boer JMA, Olsen A, Tjønneland A, Simeon V, Castro-Espin C, Aune D, Heath AK, Gunter M, Colorado-Yohar SM, Zilhão NR, Dahm CC, Llanaj E, Schulze MB, Petrova D, Sieri S, Ricceri F, Masala G, Key T, Viallon V, Rinaldi S, Freisling H, and Dossus L

Subjects
Female, Humans, Male, Anthropometry methods, Body Mass Index, C-Reactive Protein analysis, Cross-Sectional Studies, Europe epidemiology, Inflammation, Phenotype, Prospective Studies, UK Biobank, United Kingdom epidemiology, Biomarkers blood, Body Fat Distribution
Abstract

Background: The allometric body shape index (ABSI) and hip index (HI), as well as multi-trait body shape phenotypes, have not yet been compared in their associations with inflammatory markers. The aim of this study was to examine the relationship between novel and traditional anthropometric indexes with inflammation using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) and UK Biobank cohorts., Methods: Participants from EPIC (n = 17,943, 69.1% women) and UK Biobank (n = 426,223, 53.2% women) with data on anthropometric indexes and C-reactive protein (CRP) were included in this cross-sectional analysis. A subset of women in EPIC also had at least one measurement for interleukins, tumour necrosis factor alpha, interferon gamma, leptin, and adiponectin. Four distinct body shape phenotypes were derived by a principal component (PC) analysis on height, weight, body mass index (BMI), waist (WC) and hip circumferences (HC), and waist-to-hip ratio (WHR). PC1 described overall adiposity, PC2 tall with low WHR, PC3 tall and centrally obese, and PC4 high BMI and weight with low WC and HC, suggesting an athletic phenotype. ABSI, HI, waist-to-height ratio and waist-to-hip index (WHI) were also calculated. Linear regression models were carried out separately in EPIC and UK Biobank stratified by sex and adjusted for age, smoking status, education, and physical activity. Results were additionally combined in a random-effects meta-analysis., Results: Traditional anthropometric indexes, particularly BMI, WC, and weight were positively associated with CRP levels, in men and women. Body shape phenotypes also showed distinct associations with CRP. Specifically, PC2 showed inverse associations with CRP in EPIC and UK Biobank in both sexes, similarly to height. PC3 was inversely associated with CRP among women, whereas positive associations were observed among men., Conclusions: Specific indexes of body size and body fat distribution showed differential associations with inflammation in adults. Notably, our results suggest that in women, height may mitigate the impact of a higher WC and HC on inflammation. This suggests that subtypes of adiposity exhibit substantial variation in their inflammatory potential, which may have implications for inflammation-related chronic diseases., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results